Hydrix Limited's (ASX:HYD) Gavin Coote speaks to Proactive's Andrew Scott soon after announcing the US Food and Drug Administration has approved the upgraded battery for the AngelMed Guardian device for commercial release in the USA. He says the Guardian is the world’s only implantable cardiac monitor intended to detect and alert patients of a potential heart attack.
Hydrix Limited hails US FDA approval for AngelMed's Guardian device
